Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Single-Cell Transcriptomic Analysis Reveals γδ T-Cell Infiltration and Presence of Immune Regulatory Molecules in Biliary Tract Cancer Microenvironment.

American journal of clinical oncology·2026
Same author

Risk of CKD in biopsy-proven metabolic dysfunction-associated steatotic liver disease.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Implementation of evidence-based alcohol policies to reduce alcohol-related harm and liver disease to advance public health in Europe.

The Lancet regional health. Europe·2026
Same author

Safety and Efficacy of Neoadjuvant Therapy in Cholangiocarcinoma: Protocol for a Systematic Review and Meta-Analysis.

JMIR research protocols·2026
Same author

Complete Immunosuppression Withdrawal After Liver Transplantation: An International Multicenter Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective.

Gut·2026

相关实验视频

Updated: May 14, 2026

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

9.3K

定义酒精相关性肝病的风险,使用末期肝病模型.

Richard Parker1,2, Guru Aithal3, Michael Allison4

  • 1Leeds Liver Unit, St James's University Hospital, Leeds, United Kingdom.

The American journal of gastroenterology
|July 17, 2025
PubMed
概括
此摘要是机器生成的。

这项研究描述了与酒精有关的肝病 (ALD) 的长期结果,发现末期肝病 (MELD) 模型得分有效地预测了与肝脏相关的死亡率和肝脏移植风险.

关键词:
与酒精相关的肝脏疾病自然历史,自然历史.风险预测风险预测

更多相关视频

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

11.9K
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.3K

相关实验视频

Last Updated: May 14, 2026

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

9.3K
The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

11.9K
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.3K

科学领域:

  • 肝病学 肝病学是一种肝病学.
  • 内部医学 内部医学
  • 临床预后 临床预后

背景情况:

  • 酒精相关性肝病 (ALD) 是疾病和死亡的重要原因之一.
  • 现有的ALD预后得分往往缺乏长期预测准确性.
  • 了解ALD的自然史和长期风险对于患者管理至关重要.

研究的目的:

  • 描述长期与酒精相关的肝病 (ALD) 的自然史.
  • 评估和定义ALD患病率和死亡率的风险预测,包括非肝脏原因.
  • 在大型ALD队列中评估MELD等预后得分的预测性能.

主要方法:

  • 利用了WALDO队列,包括734名活检证明的ALD患者.
  • 使用曲线下的动态面积和C指数评估预后得分.
  • 在外部队列中,为末期肝病模型 (MELD) 推导并验证的风险估计.

主要成果:

  • 在平均4.9年的时间里,240名患者死于肝脏疾病或接受肝脏移植 (LT),114人死于非肝脏原因.
  • 根据ALD的严重程度,与肝脏相关的死亡或LT发生率有显著差异:47%的非补偿性肝硬化,40%的与酒精有关的肝炎,13%的补偿性肝硬化和7.4%的没有肝硬化的患者.
  • 末期肝病模型 (MELD) 评分显示了1年死亡率/LT的最佳预测准确度 (AUC 0.853),与MELD3.0和Child-Turcotte-Pugh评分相似.

结论:

  • 这项研究阐明了与酒精有关的肝病的自然史.
  • 末期肝病模型 (MELD) 评分有效地定义了ALD频谱中各种结果的风险.
  • 使用MELD评分进行风险分层验证并适用于ALD患者的长期预后.